AgomAb Therapeutics N.V. (AGMB)
$8.69-1.36%Close
SELL
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $428M
- Beta
- 1.80
- P/E (TTM)
- -9.83
- Short % float
- 2.76%
- Days to cover
- 7.1
- SI change
- +15.4%
- 1W
- -1.25%
- 1M
- -28.54%
- vs SPY 1W
- -1.11%
- vs SPY 1M
- -31.04%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 17
- VALUE
- 9
- GROWTH
- 47
- GARP
- 6
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-11.8%
REV YoY-
ROE-19.7%
EPS YoY-
ROA-12.3%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-9.83
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B1.43
P/FCF-
EV/EBITDA-4.53
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E0.43
ALTMAN Z-
CURR RATIO12.88
ND/EBITDA-
BETA1.80
Company news
FAQ
- What is LOPJLB’s current signal on AGMB?
- LOPJLB’s latest quantitative signal on AgomAb Therapeutics N.V. American Depositary Shares (AGMB) is SELL. Signals are updated daily.
- What market regime is AGMB in?
- LOPJLB classifies each ticker into BULL, RECOVERY, BEAR, or CRISIS regimes using a Hidden Markov Model.
- What does AgomAb Therapeutics N.V. American Depositary Shares (AGMB) do?
- AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing novel, disease-modifying therapies. Its primary focus lies in immunology and inflammatory ailments, particularly chronic fibrotic conditions where significant unmet medical needs persist. Its innovative pipeline features several promising candidates, including Ontunisertib (AGMB-129), an orally admini…